HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Optimizing mammography: A matter of technology, guidance and individualized risk Jennifer Byrne
-
- Should AI interpretation of mammograms become widespread in clinical practice?
- What is STING’s real name? Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
- APP-provided telehealth can ‘help fill gaps’ in cancer care during pandemic David L. Jennings II, MSN, RN, AGPCNP-BC
- Slicing the pie: Personalized medicine changing pancreatic cancer outcomes Alexander Raufi, MD
- Global trial ‘aligned around a single mission’ of advancing pediatric leukemia treatments Jennifer Byrne
- Heparin may neutralize virus that causes COVID-19 Jennifer Byrne
- ASH issues new guidelines on treatment of AML for older adults Jennifer R. Southall
- Rivaroxaban reduces recurrent VTE among patients with obesity Jennifer R. Southall
-
- Sintilimab plus pemetrexed, chemotherapy extends PFS in non-small cell lung cancer subset Jennifer R. Southall
- Fewer nivolumab doses with ipilimumab appear effective in unresectable melanoma John DeRosier
- Adjuvant pembrolizumab confers durable RFS benefit in resected stage III melanoma John DeRosier
- Metronomic capecitabine maintenance extends DFS in triple-negative breast cancer Mark Leiser
- Pembrolizumab effective, safe for recurrent, metastatic cutaneous squamous cell carcinoma John DeRosier
- Anti-CD30 CAR T-cell therapy appears safe, effective in advanced Hodgkin lymphoma Drew Amorosi
- Three-drug induction regimen leads to high response rates after transplantation in myeloma John DeRosier
- Minimally invasive surgery may increase risk for death in early-stage gynecologic cancers Jennifer R. Southall
-
- Yearly mammography beginning at age 40 years may reduce breast cancer mortality John DeRosier
- Genetic testing may benefit some postmenopausal women with breast cancer Jennifer R. Southall
- Negative perceptions of ED care a barrier for patients with sickle cell disease John DeRosier
- Dabrafenib-trametinib combination active in BRAF-mutated biliary tract cancer Mark Leiser
- Hypofractionated, conventional radiation therapy show similar long-term efficacy in prostate cancer Drew Amorosi
- Addition of radiotherapy to chemotherapy extends OS in metastatic nasopharyngeal carcinoma John DeRosier
- FDA approves Xpovio for relapsed or refractory DLBCL
- FDA approves Tecentriq plus Cotellic and Zelboraf for advanced melanoma
-
- Nine investigators to share $6.75 million for blood cancer research
- USC appoints cancer physician in chief